Inflammation versus neurodegeneration: consequences for treatment.

Inflammation is assumed to be the main driver of neurodegeneration in multiple sclerosis. However there is evidence that questions this hypothesis: Data from pathological studies and from imaging have shown that neuronal/axonal damage occurs early in lesion formation and at the earliest clinical sta...

Full description

Bibliographic Details
Main Author: Palace, J
Format: Journal article
Language:English
Published: 2007
_version_ 1797050259669516288
author Palace, J
author_facet Palace, J
author_sort Palace, J
collection OXFORD
description Inflammation is assumed to be the main driver of neurodegeneration in multiple sclerosis. However there is evidence that questions this hypothesis: Data from pathological studies and from imaging have shown that neuronal/axonal damage occurs early in lesion formation and at the earliest clinical stage of the disease. Additionally axonal damage itself can lead to inflammation and laboratory and clinical observations suggest that inflammation may be neuroprotective. Finally, clinical trials reveal that immunosuppression does not have the predicted effect on axonal damage and disability. Clearly if inflammation is not the primary event but a secondary phenomenon this has important implications in developing treatment regimes.
first_indexed 2024-03-06T18:02:32Z
format Journal article
id oxford-uuid:004e565c-e936-40d4-87d3-47d7bc76cdc8
institution University of Oxford
language English
last_indexed 2024-03-06T18:02:32Z
publishDate 2007
record_format dspace
spelling oxford-uuid:004e565c-e936-40d4-87d3-47d7bc76cdc82022-03-26T08:28:43ZInflammation versus neurodegeneration: consequences for treatment.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:004e565c-e936-40d4-87d3-47d7bc76cdc8EnglishSymplectic Elements at Oxford2007Palace, JInflammation is assumed to be the main driver of neurodegeneration in multiple sclerosis. However there is evidence that questions this hypothesis: Data from pathological studies and from imaging have shown that neuronal/axonal damage occurs early in lesion formation and at the earliest clinical stage of the disease. Additionally axonal damage itself can lead to inflammation and laboratory and clinical observations suggest that inflammation may be neuroprotective. Finally, clinical trials reveal that immunosuppression does not have the predicted effect on axonal damage and disability. Clearly if inflammation is not the primary event but a secondary phenomenon this has important implications in developing treatment regimes.
spellingShingle Palace, J
Inflammation versus neurodegeneration: consequences for treatment.
title Inflammation versus neurodegeneration: consequences for treatment.
title_full Inflammation versus neurodegeneration: consequences for treatment.
title_fullStr Inflammation versus neurodegeneration: consequences for treatment.
title_full_unstemmed Inflammation versus neurodegeneration: consequences for treatment.
title_short Inflammation versus neurodegeneration: consequences for treatment.
title_sort inflammation versus neurodegeneration consequences for treatment
work_keys_str_mv AT palacej inflammationversusneurodegenerationconsequencesfortreatment